Histamine-2 blockers are commonly prescribed for patients with gastroesophageal reflux disease, also known as GERD. Famotidine is an effectual treatment and histamine-2 blocker used to treat many of these patients, also known by the household names Pepcid, Pepcid AC and Mylanta. With the patent for Pepcid AC geltabs expiring on December 29. 2015, researchers are seeking to obtain famotidine to begin working on applicable generic options of this commonly used product. Famotidine is efficacious at decreasing the amount of acid the stomach produces, thus providing relief for the estimated 33 percent of people in the United States with this acid reflux condition. Famotidine, CAS# 76824-35-6, is essential for treating this chronic gastrointestinal disorder, and in the U.S. this condition creates costs approaching 10 billion dollars yearly, according to Livestrong online.
Common symptoms of GERD include heartburn, or a burning feeling in your chest after eating, frequent belching, an increased amount of saliva, regurgitation of your stomach contents back into your throat, a lump felt in the throat when swallowing and sharp pains in the chest when eating or drinking. Famotidine blocks some of the signals that tell your stomach to produce acid, and also neutralizes stomach acids already present. Side effects of famotidine are mild, and may include dizziness, constipation, diarrhea and headache. Famotidine is also used to treat ulcers of the stomach or small intestine, and Zollinger-Ellison syndrome, which is when patients experience tumors in the pancreas or small intestine that cause increased production of stomach acid. Offered in both 20 and 40 milligram tablets or geltabs, famotidine is best when administered in the evening each day.
One landmark study regarding the brand Pepcid found great success with the treatment of adult patients with duodenal ulcers. This multicenter, double-blind study which took place in the U.S. compared 40 milligrams of famotidine (Pepcid) to a placebo. Results indicated a staggering 70% of patients treated with famotidine were completely healed by week four of their treatment. In U.S. studies completed on patients with GERD, both with and without endoscopic evidence of erosion or ulceration, famotidine (Pepcid) was effective and safe. The aforementioned study compared 20 and 40 milligrams, given twice daily with a placebo. Patients who received 40 milligrams of famotidine displayed the most progress, with a 69% endoscopic healing at the culmination of 12 weeks of treatment. Patients dosed with 20 milligrams of famotidine (Pepcid) gleaned a 54% rate of endoscopic healing. These fruitful findings indicate a need for generic variations of this reliable drug. LGM Pharma provides API famotidine for research and development purposes.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.